Skip to main content
OpenTrials
Completed

NCT Number: NCT00987142

Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa

A phase II, comparative, open label, prospective, multicentre clinical trial where each patient will undergo two procedures; implant of a patch of cultured chimeric skin (experimental therapy) in a half of the skin lesion and an occlusive non-adherent dressing (control) in the other half for 12 months of follow-up in two Spanish centres.

Completed

Looking for future studies?

Notify Me

Key information

Age range

28 day and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Fundación Mir-Mir, Barcelona, Spain

Loading trial locations.

About this study

Reconstruction of interdigital commisures in patients with severe skin syndactyly using laminar grafts that will be uniformly and systematically taken with an electrical or compressed air dermatome on an aseptic area and with the same extent and depth in microns in all patients.

Immediately after the surgical procedure, a patch of cultured chimeric skin (experimental therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non - adherent dressing (control) will be implanted in the other half.

Patients will initially be followed up every two days until epithelisation occurs (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes over 28 days of age.
  • Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated.
  • Patients whose legal guardians have given written informed consent for participation in the study before any study procedure is performed.
  • Patients aged ≥ 12 years who have given written informed consent for participation in the study before any study procedure is performed.

Exclusion criteria

  • Women of childbearing age not using effective contraceptive methods (oral contraception)
  • Pregnant or nursing women
  • Documented or suspected hypersensitivity to any of the therapeutic agents included in the study, including anaesthetic drugs.
  • Patients with a history of malignant tumor in the past 5 years
  • Patients with a diagnosis of active tuberculosis at the time of recruitment
  • Patients with prior positive markers for any of the following pathogens: hepatitis b and c, hiv-1 and hiv-2
  • Patients with a history of clinically relevant hepatic, gastrointestinal, haematological, pulmonary, or neurological disease no directly related to epidermolysis bullosa.
  • Any other medical condition which, in the investigator´s judgment, might interfere with optimal participation in the study or involve a significant risk for the patient.
  • Alcoholism, drug addiction, psychiatric disorders, or other factors present in legal guardians which,in the investigator´s judgment may complicate patient participation in the study.

Treatment and study plan

CX501

Drug

Cultured chimeric skin

Occlusive non adherent dressing

Device

Application of an occlusive non adherent dressing in the skin donor site

Primary outcomes

  1. Time to epithelization

    Time frame: 21 days

Secondary outcomes

  1. Fibroblast persistence

    Time frame: 3, 8 and 12 months

  2. Incidence of Adverse Events

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Tigenix S.A.U.

Industry

Registry information

Official study title

A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa

Acronym: TCEB

Important dates

Study start
2006
Primary completion
2010
Study completion
2010
First posted
Sep 30, 2009
Registry last updated
Aug 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.